Prescription Monitoring Programs: An Integrative and Intuitive Map to Guide Your Investigation
Janeen Dahn Ph.D., FNP-C
Arizona State Board of Nursing
Objectives Following this presentation, you will… •  Identify issues with overuse, misuse, and abuse of controlled substances •  Identify how to access the Prescription Drug Monitoring Program (PDMP) •  Analyze the PDMP •  Integrate PDMP data with healthcare records •  Understand how to use the PDMP •  Recognize the limitations of the PDMP Why Do We Care? •  Opioids are the most widely misused or abused Rx and are involved in most Rx related overdoses •  In 2009, non medical users of psychotherapeutics (prescription opioid pain relievers, tranquilizers, sedatives, and stimulants) were similar to #s of 1st time Marijuana users Office of National Drug Control Policy. (2011) Retrieved from https://www.whitehouse.gov/ondcp/ondcp-­‐fact-­‐sheets/prescription-­‐drug-­‐
monitoring-­‐programs Why Do We Care? •  In 2010, 6 of the top 10 substances used by 12th graders were pharmaceuticals •  In 17 states drug-­‐induced deaths are now the leading cause of injury death https://www.whitehouse.gov/sites/default/files/ondcp/Fact_Sheets/
pdmp_fact_sheet_4-­‐8-­‐11.pdf Why Do We Care? •  In 2013 ~ 2 Million Americans abused Rx pain meds •  Most common drugs in overdose deaths include: •  Hydrocodone (e.g. Vicodin) •  Oxycodone (e.g. OxyContin, Percocet) •  Oxymorphone (e.g. Opana) •  Methadone (especially when prescribed for pain) •  Between 1997 -­‐2007 treatment admissions for overdose increased 4 fold. Statistics • 
70% of people who abused prescription pain relievers got them from friends or relatives • 
Data from the National Survey on Drug Use and Health show that nearly 1/3 of people aged 12 and over who used drugs for the first time in 2009, began using a prescription drug non-­‐medically http://www.whitehouse.gov/ondcp/prescription-drug-abuse
• 
Each day, almost 7,000 people are treated in the ER for RX overdose Nationwide… • 
Approximately 15,000 people died every year
from overdoses involving prescription pain
killers, more than those who die from heroin
and cocaine combined.
Center for Disease Control and prevention (2013). Prescription
Painkiller Overdoses in the U.S. Retrieved from http://www.cdc.gov/Features/VitalSigns/PainkillerOverdoses/index.html
• 
15,000 died in 2008 – more than triple the
4,000 people killed by prescription drugs in
1999
Center for Disease Control and prevention (2013). Prescription Painkiller Overdoses in the U.S. Retrieved from
http://www.cdc.gov/Features/VitalSigns/PainkillerOverdoses/index.html
Why Do We (as regulators) Care? •  Healthcare provider with active/untreated substance abuse disorder (SUD) puts patients at risk •  Reckless prescribing to persons with SUD or sell/provide the drugs to others puts the public at risk Street Value •  Oxycodone 30mg = $30/each •  Percocet = $1 per mg •  OxyContin 80mg = $80/each •  Methadone = $5 -­‐ $10/each •  Hydrocodone (Vicodin) = $3 -­‐ $10/each PDMP -­‐ What is it? •  Prescription Drug Monitoring Programs (PDMP) •  Controlled Substance Utilization Review and Evaluation System (CURES) •  Prescription Monitoring Program (PMP) •  Controlled Substance Prescription Monitoring Program (CSPMP) •  Controlled Substance Database Program (CSD) •  Michigan Automated Prescription System (MAPS) •  Kentucky All Schedule Prescription Electronic Reporting (KASPER) Who Uses the PDMP? •  Statutory authority •  Originally developed for law enforcement to identify patterns of misuse, diversion, or excessive prescribing •  Prescribers •  Regulators •  Pharmacists •  Training •  Credentials •  Registration •  Tutorial Identify how to access the PDMP Status of Prescription Drug Monitoring Programs (PDMPs) Prescription Drug Monitoring Program Training and Technical Assistance Center Authorized Recipients – Licensing/
Regulatory Boards © 2015 Research is current as of December 2014. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites and direct communications with state PMP administrators. Please contact Heather Gray at (703) 836-­‐6100, ext. 114 or [email protected] with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902. Morphine Equivalency Dosing (MED) •  System to equate different opiates and potencies into a standard morphine equivalent value •  Conversion chart created by Center for Disease Control (CDC) •  For each ACTIVE prescription then combined into one daily MED value •  “Press Pause” at 100 MED Analyze the PDMP How to use the PDMP? Must have a NEXUS to the case •  For the Respondent who is a patient (Respondent’s prescription profile) •  Unusual behavior/impaired/DUI •  For the Respondent who is a provider •  Prescribing concerns •  The PDMP is a TOOL used to address prescription drug diversion, misuse, and abuse. •  Doctor shopping •  Patterns of inappropriate prescribing Analyzing the PDMP •  Red Flags for Patient Investigation • 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Multiple pharmacies Multiple providers Escalating dosages Multiple address Similar birthdates Pattern of early refills Cash pay Volume and dose Street value? Multiple substances Oxycodone 30mg Back pain? New And Old OxyContin Pills 80-­‐milligram tablets of the current OxyContin formula (left) and the previous OxyContin formula (right) Old vs. New The pre-­‐2010 OxyContin pill crushes into grains (left) while the newer formula is more difficult to break up (right). Analyzing the PDMP •  Red Flags for Prescriber Investigation •  Multiple pharmacies •  Multiple providers •  Escalating dosages •  Early refills •  High dosages high volumes •  Family members of patient or provider •  Same med – Oxycontin 30mg •  “Pill mill” Integrate PDMP data with healthcare records Integrate PDMP Data with Healthcare Records •  Personal Characteristics of Patient •  Prescription not consistent with diagnostic evidence •  Doctor hopping •  Different names with same address •  Family members getting same drug •  UDS not consistent with prescriptions •  Excuses for lost/stolen prescriptions •  Early refills •  Ping ponging between drugs •  Request for specific meds/higher doses Personal Characteristics of Patient •  Employment issues: •  “Documentation” errors •  Frequent absences •  ER/ICU (frequent and high drug usage) •  Nights/weekends/overtime •  DUI •  Legal issues •  What type of providers are they seeing? •  Are they impaired? Or do they have other medical issues? Integrate PDMP Data with Healthcare Records •  Characteristics of Prescriber Investigation •  Replacement Rx •  Sloppy documentation/template •  High pain pt population (not consistent with specialty) •  High daily pt volume •  Communication with other providers? •  Response to PMP unexpected findings •  UDS and results Personal Characteristics of Provider •  Characteristics of Prescriber Investigation •  Lack of Knowledge ? Or Misuse/Abuse and/or Sale? •  Pain agreement •  Consistent with national guidelines •  Cash visits •  Same drug over and over •  Law enforcement and DEA interest •  Consistent with genuine medical office •  (no sign out front, voice mail only) Standard of Care Standard of Care # 1 Prescribing Long-­‐Term Opioid Medications: Prior to prescribing long-­‐term opioid medications for chronic non-­‐malignant pain, it is standard of care for an NP to conduct an appropriate evaluation of the pain problem and identify the pain generator. This evaluation includes the NP taking a pain history, reviewing the patient’s medical records, conducting a targeted physical exam, taking a drug history including verification of current prescriptions, and considering concomitant medical/psychiatric problems that may impact pain management. Each patient’s treatment plan should be individualized, and include consideration of a multidisciplinary approach/collaboration with other medical experts, as appropriate Standard of Care Deviation of Standard of Care #1 From on or about xxxxxx through xxxxx Respondent treated patient XX for Chronic pain with long-­‐term opioid medications. The medical record fails to demonstrate that Respondent conducted an appropriate evaluation of the pain problem, which identified the pain generator. This medical record lacks evidence that Respondent took a pain history, reviewed the patient’s medical records, or conducted a targeted physical exam… Standard of Care Standard of Care # 2 H&P for Chronic Pain Patients: Pain assessment should occur during initial evaluation, after each new report of pain, at appropriate intervals and after each pharm intervention. The evaluation should include the nature and intensity of the pain, current and past treatments for pain, the effect of the pain on physical and psychological function, and history of substance abuse. The patient’s health history should be corroborated by reviewing the patient’s health care records and/or speaking with the patient’s former health care providers Standard of Care Standard of Care # 3 Periodic Urine Drug Screening Evaluation of the chronic pain patient should include periodic urine drug screen testing to detect the presence of the prescribed medications and presence of illegal or illicit substances. Standard of Care Standard of Care # 4 Diagnostic Evaluations Evaluation of the chronic pain patient should include diagnostic evaluations such as blood test, radiologic exams, neurophysiologic exams, and psychological evaluations as indicated Understand how to use the PDMP How to use the PDMP •  Identify your Nexus •  Remember it is just a tool in your investigation to find supporting evidence •  Identify concerning prescribing patterns •  Obtain a copy of original prescription with provider signature •  Compare signatures •  Verify quantities •  Verify the medication was actually picked up •  Request medical records •  Request prescription profiles from pharmacy/
insurance •  Compare PDMP to medical record How to use the PDMP •  PMP During an Interview with prescriber •  “What is your practice when prescribing…” •  Step dosing, quantities, combinations •  If deviation, show PMP •  REMEMBER THE PMP IS JUST A TOOL How to use the PDMP •  PMP During an Interview with Patient •  What medications have been prescribed to you and by who? •  How often? How many providers? •  What for? •  Show patient PMP if the story doesn’t fit •  REMEMBER THE PMP IS JUST A TOOL Recognize the limitations of the PDMP Recognize the limitations of the PDMP •  Who contributes and who does not •  Dispensing from office •  Federal facilities •  Methadone clinics •  Federal healthcare facilities (e.g. Department of Veterans Affairs, Department of Defense, and Indian Health Service) are not required and do not generally report to state PDMPs Recognize the limitations of the PDMP •  Human error •  Illegible prescriber name ? Correct prescriber •  “Date filled” •  Up to a 2-­‐week lag in data entry •  State Borders U.S. Department of Veterans Affairs Pharmacies Reporting to PDMP
VT
ME
WA
MT
ND
OR
UT
CO
KS
CA
AZ
OK
NM
IA
IL
TX
IN
PA
MO
NJ
DE
OH
WV VA
DC
KY
MD
NC
TN
SC
AR
MS
AK
CT
MI
WY
RI
NY
WI
NE
NV
MA
MN
SD
ID
NH
AL
GA
LA
FL
All VA Pharmacies Reporting
HI
Some VA Pharmacies Reporting
No VA Pharmacies Reporting
GU
Research is current as of March 16, 2015
PDMP InterConnect Participation •  28 PDMPs are actively sharing data today •  Expect 35 PDMPs to be connected and sharing data by the end of 2015 Prescription Drug Monitoring Programs (PDMPs) Interstate Data Sharing Status
VT
ME
WA
MT
ND
OR
UT
CO
KS
CA
AZ
OK
NM
IA
IL
TX
IN
PA
MO
NJ
DE
OH
WV VA
DC
KY
MD
NC
TN
SC
AR
MS
AK
CT
MI
WY
RI
NY
WI
NE
NV
MA
MN
SD
ID
NH
AL
GA
LA
FL
HI
GU
Engaged in interstate data sharing *
Not engaged in interstate data sharing
Summary Putting the pieces together • Identify how to access the PDMP • Analyze the PDMP • Integrate PDMP data with healthcare records • Understand how to use the PDMP • Recognize the limitations of the PDMP Questions? Comments? Janeen Dahn PhD, FNP-­‐C email: [email protected]